AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00450801
Drug: Decadron
RxNorm normalized name: Decadron
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Decadron 10 mg IV on Day 1, Cycles 1 and 3
Trial: NCT00249236
Drug: Risperidone, oral tablets
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00594269
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Discontinuation
Trial: NCT02117596
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours).
Trial: NCT00838916
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: insulin glargine
Trial: NCT00594269
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinuation
Trial: NCT00594269
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinuation
Trial: NCT00594269
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinuation
Trial: NCT00594269
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinuation
Trial: NCT00958269
Drug: dutogliptin
RxNorm normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg QD
Trial: NCT00958269
Drug: dutogliptin
RxNorm normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg QD
Trial: NCT00958269
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg QD
Trial: NCT00958269
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg QD
Trial: NCT00829257
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate Accuhaler 250ug b.i.d.
Trial: NCT00829257
Drug: Seretide
RxNorm normalized name: seractide
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
Trial: NCT00601796
Drug: All-trans retinoic acid (ATRA)
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid was given (150/mg/m\^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
Trial: NCT02172508
Drug: Tiotropium Inhalation Capsule
RxNorm normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01064037
Drug: Cinaciguat (BAY58-2667)
RxNorm normalized name: Cinaciguat
DrugBank: Cinaciguat (DB16126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 150 µg/h during 48h.
Trial: NCT01064037
Drug: Cinaciguat (BAY58-2667)
RxNorm normalized name: Cinaciguat
DrugBank: Cinaciguat (DB16126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 100 µg/h during 48h
Trial: NCT01064037
Drug: Cinaciguat (BAY58-2667)
RxNorm normalized name: Cinaciguat
DrugBank: Cinaciguat (DB16126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 50 µg/h during 48h
Trial: NCT02062632
Drug: Doxepin Hydrochloride
RxNorm normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02212028
Drug: prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: the effects of whole tablets versus crushed tablets will be compared
Trial: NCT01043666
Drug: YM178
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01043666
Drug: tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00626522
Drug: Aclidinium bromide and formoterol
RxNorm normalized name: Aclidinium Bromide and Formoterol Fumarate Inhalation Powder
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00626522
Drug: Aclidinium bromide and formoterol placebo
RxNorm normalized name: aclidinium bromide / formoterol fumarate Inhalant Product
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT04224428
Drug: Fexofenadine Pill
RxNorm normalized name: fexofenadine Pill
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fexofenadine tablets 60 mg once daily will be taken for six months
Trial: NCT03618238
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg daily for continus 14 days every 21 days
Trial: NCT00373776
Drug: miltefosine 2.5 mg/kg/day for 28 days
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01461512
Drug: heme arginate administration
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heme arginate 1 mg/kg body weight 24 hours prior to ischemia
Trial: NCT01852539
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
Trial: NCT01852539
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 2.0 mg/kg was administrated
Trial: NCT03589885
Drug: Secukinumab 2 mL auto-injector
RxNorm normalized name: secukinumab Auto-Injector
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
Trial: NCT03589885
Drug: Secukinumab 1 mL prefilled syringe
RxNorm normalized name: secukinumab Prefilled Syringe
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Trial: NCT00663455
Drug: Reduction of cyclosporine A (CSA)-dosing
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
Trial: NCT00171314
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole tablets 2.5 mg/day/taken orally for 5 years.
Trial: NCT04508894
Drug: Supraclavicular Brachial Plexus Block with bupivacaine
RxNorm normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug: 20 ml 0.5%bupivacaine plus 20 ml 0.9% normal saline is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block
Trial: NCT04508894
Drug: Supraclavicular Brachial Plexus Block with Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1mg\\kg ketamine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block
Trial: NCT04508894
Drug: Supraclavicular Brachial Plexus Block with Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1µg\\kg dexmedetomidine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block
Trial: NCT00070473
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02250612
Drug: 1 drop of 0.5 % timolol maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02105116
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02105116
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02105116
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01114568
Drug: Ertugliflozin 10 mg tablet
RxNorm normalized name: ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
Trial: NCT01114568
Drug: Ertugliflozin OC Fast
RxNorm normalized name: OCE-205
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Formulation B) Ertugliflozin 10 mg OC Fast
Trial: NCT01114568
Drug: Ertugliflozin OC Slow
RxNorm normalized name: OCE-205
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Formulation C) Ertugliflozin 10 mg OC Slow
Trial: NCT00773968
Drug: Methoxy Polyethylene Glycol-Epoetin Beta
RxNorm normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
Trial: NCT02368314
Drug: Sodium Enoxaparine
RxNorm normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
Trial: NCT03203850
Drug: Deferasirox FCT
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Taken orally once per day (QD) as a film coated tablet (FCT)
Trial: NCT01331850
Drug: Copegus
RxNorm normalized name: Copegus
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg or 1200 mg daily oral doses for 24 weeks
Trial: NCT03112382
Drug: vitamin A and E
RxNorm normalized name: vitamin A / vitamin E
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00896168
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
Trial: NCT05283694
Drug: risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous Injection via prepared syringe
Trial: NCT05283694
Drug: risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous Injection via syringe pump
Trial: NCT00563108
Drug: Basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01331850
Drug: Copegus
RxNorm normalized name: Copegus
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg or 1200 mg daily oral doses for 48 weeks
Trial: NCT03675022
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The investigational drug is dupilumab, 300mg in 2ml solution for subcutaneous application. All Patients will receive dupilumab, 300mg, every two weeks (8 subcutaneous injections total).
Trial: NCT04649398
Drug: Nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
Trial: NCT01096043
Drug: Strata 1 CXL-1020
RxNorm normalized name: ANGUILLA ROSTRATA BLOOD SERUM
DrugBank: CXL-1020 (DB15326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
Trial: NCT01096043
Drug: Strata 2 CXL-1020
RxNorm normalized name: ANGUILLA ROSTRATA BLOOD SERUM
DrugBank: CXL-1020 (DB15326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
Trial: NCT01331850
Drug: Pegasys
RxNorm normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 microgram subcutaneously once weekly for 24 weeks
Trial: NCT01331850
Drug: Pegasys
RxNorm normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 microgram subcutaneously once weekly for 48 weeks
Trial: NCT01331850
Drug: danoprevir
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral doses twice a day for 24 weeks
Trial: NCT01331850
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg oral doses twice a day for 24 weeks
Trial: NCT00986050
Drug: Abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
Trial: NCT01096043
Drug: Strata 3 CXL-1020
RxNorm normalized name: ANGUILLA ROSTRATA BLOOD SERUM
DrugBank: CXL-1020 (DB15326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
Trial: NCT01238133
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01238133
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00004986
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02864992
Drug: Tepotinib
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
Trial: NCT01009983
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01009983
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04083898
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine will be administered on a 28-day cycle as follows
Trial: NCT04083898
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be administered on a 28-day cycle as follows
Trial: NCT03833999
Drug: Ondansetron 8mg
RxNorm normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting
Trial: NCT03833999
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
Trial: NCT01560897
Drug: Oral C13
RxNorm normalized name: SOR-C13
DrugBank: SOR-C13 (DB15366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of C13 and follow up of the ureogenesis
Trial: NCT04897958
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix dispensing claim is used as the reference group.
Trial: NCT04897958
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide dispensing claim is used as the exposure group.
Trial: NCT02804594
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1250 mg of N- acetyl cysteine taken three times daily
Trial: NCT02420223
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02048943
Drug: dovitinib lactate
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02048943
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02048943
Drug: paclitaxel albumin-stabilized nanoparticle formulation
RxNorm normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01071096
Drug: OnabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm.
Trial: NCT01071096
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm.
Trial: NCT00511953
Drug: Gabapentin Extended Release tablets
RxNorm normalized name: gabapentin Extended Release Oral Tablet
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1800mg
Trial: NCT00511953
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1800mg
Trial: NCT00485589
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00131677
Drug: tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: study product taken daily
Trial: NCT01314976
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole, oral suspension, 40mg/ml.~1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents.
Trial: NCT00502632
Drug: Urokinase and Dornase alfa
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days
Trial: NCT00502632
Drug: Urokinase
RxNorm normalized name: Urokinase
DrugBank: Urokinase (DB00013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* 25ml normal saline, twice daily for 4 days
Trial: NCT00205699
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: randomized to begin 12 week trial of risperidone
Trial: NCT00205699
Drug: olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: randomized to begin 12 week trial of olanzapine
Trial: NCT00205699
Drug: aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: randomized to 12 week trial of aripiprazole
Trial: NCT00871377
Drug: High Dose Fish Oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids, 1060 mg EPA + DHA